 Since T4 thyroxine is a potent growth factor in numerous cancer types, the interventional approach will be to achieve thyroxine deprivation hypothyroxinemia.This can be achieved by using a dual approach: T3 and methimazole to provide longer term inhibition of thyroid hormone synthesis. 